Company intelligence / Profile preview
Corestemchemon
Seongnam-si, Gyeonggi-do, South Koreacorestemchemon.com ↗
- Ownership
- Private
- Employees
- ~355
- Development stage
- Other
01
Overview
Corestemchemon’s lead product, NEURONATA-R inj, is an autologous bone marrow mesenchymal stem cell therapy for ALS. The company has completed patient registration for a Phase 3 trial of NEURONATA-R and has received Expanded Access Program authorization from the US FDA. Other pipeline programs target neurodegenerative and autoimmune diseases and are in various preclinical or early clinical stages[2][3].
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Stem cell therapies (autologous bone marrow mesenchymal stem cells)[3][4]
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
NH Investment & Securities Co., Ltd.Samsung Securities Co., Ltd. provided significant funding.[4]No major pharma partnerships publicly disclosed.
Beyond the preview
Go deeper on Corestemchemon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Corestemchemon.